pathogenesis clinical manifestation pathological ... · nephrology board review 19 /0757 thaweepong...
TRANSCRIPT
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 1
Thaweepong Pajareya M.D.
Director,
Department of Pathology,
Bhumibol Adulyadej Hospital
Nephrology Board Review
19 July 2014
TOPIC
• Pathogenesis
• Clinical Manifestation
• Pathological Classification
• Therapeutic options
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 2
CAUSES OF DEATH IN SLE
1950 –1955
1956 –1962
1963 –1973
1973 –1987
1978 -2008
Patients 491 491 491 389 500
All deaths (%)
12 20 19 22 15
Death from nephritis (%)
26 36 14 4 8
Death from infections (%)
16 12 18 39 25
Rahman A et al. In Lupus Nephritis , second edition. 2011. 35 – 58.
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 3
Antigen specificity Prevalence (%)
Anti dsDNA 70 – 80
Nucleosomes 60 -90
Sm 10 – 30
α - Actinin 20
C1q 40 - 50
PATHOGENIC AUTOANTIBODIES IN SLE
Rahman A et al. N Engl J Med. 2008;358:929 – 39.
NUCLEOSOMES
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 4
INDUCTION OF SURFACE BLEB DURING APOPTOSIS
Autoimmune 2012
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 5
SYSTEMIC LUPUS ERYTHEMATOSUS
• Systemic autoimmune disorder characterized by a striking predominance and frequently development of glomerulonephritis
• Renal involvement in SLE remains the strongest predictor of overall patient morbidity and mortality
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 6
RENAL INVOLVEMENT IN SLE
• 20 – 49 % of patient during their course
• 40 – 60 % of LN patients develop during first manifestation
•More frequent in children, male , African American , Hispanics
KIDNEY INVOLVEMENT IN SLE
• Incidence differs with ethnicity
• Caucasians 12 – 33%
• African American 40 – 69 %
• Hispanic 36 – 61 %
• Asian 47 – 53%
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 7
RENAL MANIFESTATIONS OF LUPUS
• Proteinuria
• Present in almost every pts. with nephritis
• Often sufficient to be associate with some degree of edema
• May come and go spontaneously
• Severe lupus nephritis is unusual in the absence of proteinuria
Ropes, Medicine; 1964, 43, 387-391
RENAL INVOLVEMENT IN SLE
• Nephrotic syndrome
• 25% of all pts. with LN will show a nephrotic syndrome at some time in their disease course
• More common in ISN/RPS class III , IV and V
• Hematuria
• Microscopic hematuria is common, macroscopic hematuria is very rare
• Cast
• Present in about 1/3 of patients
• Granular cast , rbc cast
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 8
RENAL INVOLVEMENT IN SLE
• Hypertension
• 25 - 50% of patients were assessed as hypertensive
• Those with more severe nephritis were more commonly hypertensive (class II 17%; class IV 55% )
• HT is not often of great severity, retinopathy is usually mild; and accerelated HT is rare
RENAL MANIFESTATION IN SLE
• Abnormal Urinary abnormality
• Nephrotic syndrome
• Acute glomerulonephritis
• Rapidly progressive glomerulonephritis
• Thrombotic microangiopathy
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 9
WHEN TO TREAT ?
HOW TO TREAT ?
RISK FACTORS FOR ESRD
• Clinical characteristic
• Elevated initial serum creatinine *
• Nephrotic range proteinuria
• Low C3
• Hematocrit < 26 %
• Hypertension *
• Persistent disease activity
Berden JHM: Lupus nephritis, KI 1997,52:538-558
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 10
RISK FACTORS FOR ESRD
• Demographic characteristics
•Male gender
• Black race
• Age < 24
• Low socioeconomic status
Berden JHM: Lupus nephritis, KI 1997,52:538-558
RISK FACTORS FOR ESRD
• Treatment characteristics
• No normalization of elevated creatinine
• Treatment with prednisolone only
• Histologic characteristics
•WHO Class IV *
• Activity index > 12
• Chronicity index > 3
Berden JHM: Lupus nephritis, KI 1997,52:538-558
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 11
ISN/RPS CLASSIFICATION (2003)
• Class I Minimal mesangial lupus nephritis
• Class II Mesangial proliferative lupus nephritis
• Class III Focal lupus nephritis
• Class IV Diffuse segmental (IV-S) or global (IV-G) lupus nephritis
• Class V Membranous lupus nephritis
• Class VI Advanced sclerosing lupus nephritis
Weening JJ et al. Kidney Int 65: 521 – 530. 2004
Class I Minimal mesangial LN
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 12
Class II Mesangial proliferative LN
Class III Focal LN
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 13
Class IV Diffuse LN
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 14
Class IV-G Diffuse Global LN
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 15
Class V Membranous Lupus
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 16
CLINICAL MANIFESTATIONS OF LUPUS NEPHRITIS
Classification Inciden
ce
Active
urinary
sedime
nt
Proteinu
ria
Nephro
tic
syndro
me
Renal
insufficie
ncy
5-Yr.
renal
survival
I. Minimal < 5 % 0 0 0 0 100 %
II. Mesangial 15 % < 25 % 25–50 % 0 < 15 % > 90 %
III. Focal
lupus
nephtiris
20 % 50 % 67 % 25–33 % 10–25 % 85–90
%
IV. Diffuse
lupus
nephritis
50 % 75 % > 95 % 50 % > 50 % 60–90
%
V.
Membranous
15 % 50 % > 95 % 90 % 10 % 70–90
%
DIAGNOSIS OF LUPUS NEPHRITIS
• At present , there is not any laboratory investigation that is sensitive and specific enough for diagnosis class of Lupus Nephritis
• Lupus nephritis class must be confirmed by kidney biopsy
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 17
APPROACH
•Mild
• Proteinuria < 1 gm/24 hr
• Inactive urinary sediment
• Serum creatinine < 1.2 mg/dl (eGFR> 60 ml/min)
• Normotension
• Most likely Class I or II
• Treat extrarenal , follow up
APPROACH
• Severe
• Proteinuria > 1 gm/24 hr
• Serum creatinine > 1.2 mg/dl (eGFR < 60 ml/min)
• Usually active urinary sediment , hypertension
• Most likely Class IV , III
• Need aggressive treatment
• Kidney biopsy helpful
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 18
APPROACH
• Moderate
• Proteinuria > 1 gm/24 hr
• Serum creatinine < 1.2 mg/dl (eGFR > 60 ml/min)
• Possibly Class II , III , IV, V
• Kidney biopsy recommended to pick up severe lupus nephritis
• Class III
• Class IV
ขอ้บง่ชีใ้นการตรวจชิน้เนือ้ไต
• เพือ่ยนืยันการวนิจิฉัยโรคในรายทีม่ภีาวะไตอักเสบและสงสยัเป็น
โรคลปัูส แตม่เีกณฑก์ารวนิจิฉัยโรคลปัูสไมค่รบตาม ACR criteria
• เพือ่วางแผนรักษาในรายทีม่โีปรตนีในปัสสาวะมากกวา่ 1 กรัมตอ่วนั
• เพือ่วางแผนรักษาในรายทีม่ี active nephritic urine sediment
[เพือ่วางแผนรักษา ในรายทีต่รวจพบม ีproteinuria > 0.5 กรัม/วนั
รว่มกับม ีnephritic urine sediment (RBC > 5/HPF หรอื RBC
cast)]
• เพือ่วางแผนรักษาในรายทีต่รวจพบการท างานของไตผดิปกตแิบบ
เฉียบพลันทีไ่มท่ราบสาเหตุ
(ร่าง) ค าแนะน าในเวชปฏิบัต ิส าหรับการดแูลรักษาผู้ ป่วยโรคไตอักเสบลูปัสในประเทศไทย สมาคมโรคไตแห่งประเทศไทย 2557
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 19
ขอ้บง่ชีใ้นการตรวจชิน้เนือ้ไต
• เพือ่วางแผนรักษาในรายทีไ่ดรั้บ prednisolone
มากกวา่ 8 สปัดาหแ์ลว้ยังไมต่อบสนองตอ่การ
รักษา (ไมเ่ขา้สู ่complete response)
• เพือ่วางแผนรักษาในรายทีไ่ดรั้บการรักษาแลว้แต่
ยังมกีารท างานของไตผดิปกต ิเพือ่แยกระหว่าง
พยาธสิภาพทียั่งอยูใ่นระยะเฉียบพลัน (active)
กบัรอยโรคเกา่ในการอกัเสบเรือ้รัง (scar)
(ร่าง) ค าแนะน าในเวชปฏิบัต ิส าหรับการดแูลรักษาผู้ ป่วยโรคไตอักเสบลูปัสในประเทศไทย สมาคมโรคไตแห่งประเทศไทย 2557
TREATMENT
• No definitive cure in SLE
• Major aim of treatment
• Reduce symptoms
• Halt progression of disease
• Balancing between benefit and risks
• Infection must be excluded prior to institution of corticosteroids or cytotoxic drugs
• Pregnancy : contraception
• Need individualized , flexible approach
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 20
TREATMENT OF LUPUS NEPHRITIS
• Class I (minimal-mesangial LN) treat extrarenal
• Class II (mesangial proliferative LN)
• Proteinuria < 1 g : treat extrarenal
• Proteinuria > 3 g : treat as MCD with steroid or CNIs
KDIGO guideline for lupus nephritis. Kidney Int. 2012
TREATMENT OF CLASS III AND IVLUPUS NEPHRITIS
• Severe lupus nephritis requires four distinctly organized therapeutic strategies
Assessment of the systemic disease
Treatment of the acute phase of severe lupus nephritis (Induction therapy)
Maintenance phase (Prevent replase)
Treatment of exacerbation of lupus glomerulonephritis (Flare)
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 21
TREATMENT OF LUPUS NEPHRITIS IN 2002
• If the patient had mild FPLN or severe DPLN they got monthly IV cyclophosphamide (IVCY)
• If the patient was follow by a nephrologist or rheumatologist they got monthly IVCY
• If the patient was adult or pediatric they got monthly IVCY
TREATMENT OF LUPUS NEPHRITIS IN 2002
• If the patient had prior IVCY with or without side effects the got monthly IVCY
• Everything was based on small randomized trials many from the US-NIH
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 22
NIH LANDMARK STUDY
• Austin III HA et al. NEJM, 1986;314 : 614
• Steinberg AD, et al Arthritis Rheum 1991; 34, 945 – 950.
• Boumpas DT et al, Lancet 1992;340: 741 –745.
• Gourley et al. Ann Intern Med 1996; 549 – 557.
• Illei GG et al. Ann Intern Med 2001; 135: 248 –257.
Steinberg AD, Steinberg SC. Arthritis Rheum 1991; 34: 945-950.
NIH STUDY
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 23
NIH REGIMENTREATMENT OF PROLIFERATIVE LUPUS
NEPHRITIS
• Immunosuppressive therapy
• Prednisolone (0.5 – 1 mg/kg/d) for up to 8 weeks,
then taper (by 5 mg qod each week) to 0.25
mg/kg/qod
• Pulse methylprednisolone (1 g/m2/d for 3 days
followed by 1 g/m2/monthly for 6 to 24 months
• Pulse cyclophosphamide 0.5 – 1 g/m2 monthly for
6 months then quarterly for one year beyond
remission
Austin HA, Balow JE. Semin Nephrol, No 1, 1999: 2 – 11
DOWNSIDE IVCY
•Remission rate 60 – 70 %
•Toxicity : Herpes zoster 25%, severe infection 26%, ovarian failure 52%, avascular necrosis
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 24
NEWER THERAPY
•More efficient
•Less toxicity
EURO – LUPUS NEPHRITIS TRIAL (ELNT)
• Multicenter prospective clinical trial of 90 LN pts with proliferative LN
• High dose IVCY (6 monthly + 2 quarterly pulses) vs Low dose IVCY (500 mg q2wks x 6)
• Maintenance : AZA (2mg/kg/d) 2 wksafter IVCY
• Follow 41 months
Houssiau et al. Arthritis & Rheumatism 46: 2121 – 2131, 2002.
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 25
PROBABILITY OF REMISSION
LD
HD
Houssiau et al. Arthritis & Rheumatism 46: 2121 – 2131, 2002.
FREE OF RENAL FLARE
LD
HD
Houssiau et al. Arthritis & Rheumatism 46: 2121 – 2131, 2002.
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 26
FREE OF SEVERE INFECTION
LD
HD
Houssiau et al. Arthritis & Rheumatism 46: 2121 – 2131, 2002.
10 YEARS FOLLOW UP (ELNT)PATIENT SURVIVAL
Houssiau FA et al. Ann Rheum Dis;69: 61 – 64. 2010
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 27
COMMENT
•Not exactly NIH regiment : use AZA as maintenance
• Less severity patients compare with NIH
•Mostly Caucasians
MYCOPHENOLATE MOFETIL(MMF)
• Blocks proliferation of both B and T cells
• Inhibits antibody formation and the generation of cytotoxic T cells
• Decreases expression of adhesion of adhesion molecules on lymphocyte and endothelial cell reduction in endothelial –lymphocyte interactions
• Anti – proliferative effect
• Selective antimetabolite
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 28
MMF LANDMARK STUDY
• Chan TM, et al. NEJM 2000;343:1156 – 62.
• Chan TM, et al. J Am Soc Nephrol. 2005; 16:1076 – 1084.
• Contreras G, et al. NEJM. 2004;350:971 – 80.
• Ginzler EM, et al. NEJM 2005;353:2219 – 28.
• Apple GB et al. J Am Soc Nephrol. 2009; 20:1103 –12.
• Dooley MA et al. N Engl J Med. 2011; 365:1886-95.
MMF IN LUPUS NEPHRITIS
• Induction of remission
•Maintenance therapy of severe lupus nephritis
• Treatment of refractory case
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 29
MMF FOR INDUCTION TREATMENT
• RCT, 42 patients
• Inclusion criteria
• SLE criteria by ARA
• Renal biopsy show diffuse proliferative lupus nephritis (Class IV)
• Proteinuria > 1 gm
• Serum albumin < 3.5 g/dl
Chan TM et al. NEJM. 2000. Vol 343 :1156 - 1162
RESULTS
MMF vs Oral CYC for induction
Chan TM et al. NEJM. 2000.
343 :1156 - 1162
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 30
MMF vs Oral CYC for induction
Chan TM et al. NEJM. 2000.
343 :1156 - 1162
LONG TERM STUDY OF MMF
•Median follow up 63 months
• N = 62, 32 MMF, 30 CTX-AZA
• Comparable long-term efficacy compare with oral CTX-AZA regarding renal
preservation and prevent relapse
• Significant reduce unfavorable outcome (Infection and amenorrhea)
Chan TM et al. JASN 16: 1076 – 1084. 2005
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 31
MMF VS IVCY IN SEVERE LN(US STUDY)
• Randomized induction trial – patients
with active LN (WHO class III, IV, V)
• 24 weeks , induction period
• 140 pts, 71 MMF, 69 IVCY
•MMF : Target dose 3 g/day
• IVCY : NIH regimen (monthly for 6
months)
Ginzler EM, Dooley MA, et al. N Engl J Med 2005; 353: 2219 – 28.
RESULT
MMF IVCY P value
Complete remiss.
22.5 % 5.8 % 0.005
Partial remiss.
29.5 % 24.6 % 0.51
No remission
47.9 % 69.6 % 0.01
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 32
ADVERSE EVENTS
MMF
(N = 83)
IVCY
(N = 75)
Severe infection 1 6
Diarrhea 15 2
Lymphopenia 18 28
Amenorrhea 0 2
US STUDY
•MMF are more effective than IVCY for induction treatment
•MMF has more favorable safety profile
•Comment
• Very low CR in IVCY group
Ginzler EM, Dooley MA, et al. N Engl J Med 2005; 353: 2219 – 28.
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 33
MMF VS IVCY FOR INDUCTIONASPREVA LUPUS MANAGEMENT STUDY
GROUP (ALMS)
• International randomized controlled trial
• 370 LN class III, IV, V
• 185 IVCY (0.5 – 1 g/m2 ) monthly pulse
• 185 MMF titrate to 3 g/day
• Duration 24 weeks
• Prednisolone 60 mg/d titrate down
Apple GB, Contreras G, Dooley MA et al. J Am Soc Nephrol 2009;20:1103 – 12.
ALMS
Apple GB, Contreras G, Dooley MA et al. J Am Soc Nephrol 2009;20:1103 – 12.
No different between MMF and IVCY in induction Rx
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 34
TREATMENT OFLUPUS NEPHRITIS
Class III LN (focal LN) and class IV LN (diffuse LN) initial therapy
We recommend initial therapy with corticosteroids (1A), combined with either cyclophosphamide (1B) or MMF (1B).
We suggest that, if patients have worsening LN (rising SCr, worsening proteinuria) during the first 3 months of treatment, a change be made to an alternative recommended initial therapy, or a repeat kidney biopsy be performed to guide further treatment. (2D)
KDIGO guideline for lupus nephritis. Kidney Int. 2012
MAINTENANCE TREATMENT FOR PROLIFERATIVE LN
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 35
SEQUENTIAL THERAPY FOR PROLIFERATIVE LN IVCY INDUCTION IVCY VS AZA VS MMF MAINTENANCE
• N = 59 > 90% F 33 yo 50 % African american
•WHO III = 12, WHO IV = 46, WHO V = 1
• HT 95 %, Active serology
• NS 65 %, Albumin 2.7 g/dl, U Prot > 5g/d
• SCr. 1.6 mg/dl
Contreras G, et al, N Engl J Med; 350, 971 – 80. 2004
TREATMENT
• Induction : Monthly IVCY (500 – 1 g/m2) 4 – 7 doses with steroids
•Maintenance
• Quarterly IVCY : 20 pts
•MMF (500 – 3000 mg/d) : 20 pts
• AZA (0.5 – 3 mg/kg/d) : 20 pts
Contreras G, et al, N Engl J Med; 350, 971 – 80. 2004
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 36
IVCY
AZA
MMF
PATIENT SURVIVAL
Contreras G, et al, N Engl J Med; 350, 971 – 80. 2004
IVCY
AZA
MMF
EVENT-FREE SURVIVAL
Contreras G, et al, N Engl J Med; 350, 971 – 80. 2004
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 37
IVCY
AZA
MMF
RELAPSE FREE SURVIVAL
Contreras G, et al, N Engl J Med; 350, 971 – 80. 2004
SIDE EFFECTS
Hosp D/pt yr
(%)Amenorrhea
(%)
Infection
(%)
Major
(%)
IVCY 13 32 68 12
AZA 1* 7.5* 28* 3
MMF 1* 6.1* 21* 3
Contreras G, et al, N Engl J Med; 350, 971 – 80. 2004
Maintenance MMF and AZA
associated with
significant less hospital
days, amenorrhea and
infections than IVCY
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 38
MAINTAIN STUDY
• 105 patients with proliferative lupus
• Induction (Euro lupus)
• Pulse MP 750 mg/d for three days
• Oral Pred 0.5 mg/kg/day
• IVCY 500 mg /2 week x 6
• Maintenance
• AZA 2 mg/kg/d
• MMF 2 g/day
Houssiau FA et al. Ann Rheum Dis ; 69:2083 – 2089. 2010
MAINTAIN NEPHRITIS TRIAL
Adverse event are comparable
AZA
MMF
Houssiau FA et al. Ann Rheum Dis ; 69:2083 – 2089. 2010
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 39
ALMS MAINTENANCE TRIAL
• 370 patients from ALMS induction trial
• LN Class III, IV, V
• 227 response to induction treatment random to maintenance phase
• 116 : MMF 2 g/day (min: 1 g/day)
• 111 : AZA 2 mg/kg/day (min: 50 mg/d)
• All receive pred 10 mg/day
• Follow 36 months
Dooley MA, et al. N Engl J Med 2011;365:1886-95.
TREATMENT FAILURE
Dooley MA, et al. N Engl J Med 2011;365:1886-95.
MMF
AZA
P = 0.003
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 40
RENAL FLARE
Dooley MA, et al. N Engl J Med 2011;365:1886-95.
MMF
AZA
P = 0.03
MAINTENANCE THERAPY
•We recommend that, after initial therapy is complete, patients with class III and IV LN receive maintenance therapy with azathioprine (1.5–2.5 mg/kg/d) or MMF (1–2 g/d in divided doses), and low-dose oral corticosteroids (< 10 mg/d prednisone equivalent). (1B)
KDIGO guideline for lupus nephritis. Kidney Int. 2012
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 41
RECOMMENDATIONSEVERE LUPUS NEPHRITIS
• RPGN or multiorgan: NIH
•Others
MMF induction
Euro Lupus
NIH induction
•Maintenance
MMF or AZA
TREATMENT OF CLASS V LUPUS NEPHRITIS
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 42
TREATMENT OF LN CLASS VPRED VS IVCY VS CYA
Austin HA et al. J Am Soc Nephrol. 20:901-911. 2009
42 LMN, NS
Pred AD
Pred + IVCY AM x 6
Pred + CyA
CyA : relapse
INDUCTION IN CLASS V LN
• Pool analysis of ALMS and US study
• IVCY vs MMF for induction
• 84 Class V LN (Mostly Nephrotic)
Radhakrishnan J et al. Kidney Int. 77:152 – 160. 2010
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 43
CLASS V TREATMENT
• Only in nephrotic patient
• Prednisolone 0.5 mg/kg/day plus
•MMF
• Cyclosporine
• Pulse IVCY
GENERAL TREATMENT
•We suggest that all patients with LN of any class are treated with hydroxychloroquine (maximum daily dose of 6–6.5 mg/kg ideal body weight), unless they have a specific contraindication to this drug. (2C)
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 44
ขอ้บง่ชีใ้นการสง่ปรกึษาอายรุแพทยโ์รคไต
• ยนืยันการวนิจิฉัยโรคไตอกัเสบลปัูส ในกรณีทีม่ขีอ้
สงสยั
• ประเมนิความรนุแรงของโรคไตอกัเสบลปัูส
• วางแผนรักษาโรคไตอกัเสบลปัูส โดยเฉพาะผูป่้วยทีม่ ี
nephrotic range proteinuria หรอืมกีารท างานของไต
ผดิปกต ิหรอืไมต่อบสนองตอ่การรักษา
• รว่มตดัสนิใจและวางแผนการรักษาในภาวะพเิศษบาง
กรณี ไดแ้ก ่การตัง้ครรภ ์และการวางแผนผา่ตดั เป็นตน้
(ร่าง) ค าแนะน าในเวชปฏิบัต ิส าหรับการดแูลรักษาผู้ ป่วยโรคไตอักเสบลูปัสในประเทศไทย สมาคมโรคไตแห่งประเทศไทย 2557
TREATMENT OF LN IN 2014
• Treatment is divided into and induction and maintenance phase
• Induction therapy consists of Euro lupus regimen of IVCY or MMF
• Maintenance therapy consists of MMF or AZA
• New therapies include Rituximab based and corticosteroid free
• Everything will be studied in RCT (Belimumab, Abltacept, Laquinamod, etc.)
Nephrology Board Review 19/07/57
Thaweepong Pajareya M.D. 45
IMPORTANT MESSAGES
•Under treatment leads to renal failure, dialysis, transplantation
•Over treatment kills patients from complications
•Vigorous treatment only safe with a vigilant M.D.
• Geral B Appel, M.D